Phase II
Annovis Bio’s therapy for Alzheimer’s disease is fast-acting and has the potential for Alzheimer’s patients to significantly improve cognition and motor function, according to data presented at the Alzheimer’s Association International Conference® 2021 (AAIC®), held July 26th through 30th.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
The company’s pipeline was strengthened in the second quarter with three strategic collaborations in immuno-oncology, immuno-neurology, and HIV.
Several biotech and biopharmaceutical companies have announced new wins with the U.S. Food and Drug Administration (FDA), with these wins ranging from Investigational New Drug (IND) application approvals for cancer treatment candidates to Fast Track Designations for investigational agents aimed toward opioid use disorder (OUD).
Today is the first day of the Alzheimer’s Association International Conference 2021 (AAIC), behind held both virtually and in person in Denver, Colorado. Here’s a look at some of today’s stories.
Abeona Therapeutics’ shares popped 18.32% in pre-market trading after New York and Cleveland-based company announced magnetic resonance imaging (MRI) data from its Phase I/II Transpher A trial in San Filippo Syndrome Type A (MPS IIIA).
Updated trial data show patients treated with BioMarin Pharmaceutical’s severe hemophilia A gene therapy expressed substantially lower factor VIII levels after five years compared with one year, calling into question the drug’s long-term benefits.
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
Shares of Adverum Biotechnologies plunged more than 20% in premarket trading after the company announced it was revising its clinical development plan for investigational gene therapy candidate ADVM-022 based on safety concerns in patients with diabetic macular edema (DME).
The company said it has decided to close the study’s open-label and maintenance portions given the inability to satisfy endpoint goals.
PRESS RELEASES